Koyfin Home > Directory > Health Care > Rigel Pharmaceuticals > EV / EBITDA (ltm)

Rigel Pharmaceuticals EV / EBITDA (ltm) Chart (RIGL)

Rigel Pharmaceuticals annual/quarterly EV / EBITDA (ltm) from 2010 to 2014. Enterprise multiple, also known as the EBITDA multiple, is a ratio used to determine the value of a company. It uses the consensus estimate EBITA over the last twelve months (LTM). The enterprise multiple looks at a firm in the way a potential acquirer might by considering the company's debt, which other multiples such as P/E do not include.
  • Rigel Pharmaceuticals EV / EBITDA (ltm) for the quarter ending November 11, 2014 was 0.12 a 61.67% increase of 0.08 year over year
  • Rigel Pharmaceuticals EV / EBITDA (ltm) for the last 12 months ending November 11, 2014 was 0.12 a 61.67% increase of 0.08 year over year
  • Rigel Pharmaceuticals Annual EV / EBITDA (ltm) for 2014 was 0.12 a 60.37% increase of 0.07 from 2013
  • Rigel Pharmaceuticals Annual EV / EBITDA (ltm) for 2014 was 0.05 a 65.29% increase of 0.03 from 2013
  • Rigel Pharmaceuticals Annual EV / EBITDA (ltm) for 2014 was 0.02 a -178.64% decrease of -0.03 from 2013
Other Valuation Metrics:
  • Rigel Pharmaceuticals Market Cap for the quarter ending March 03, 2018 was $521m a 35.88% increase of 187m year over year
  • Rigel Pharmaceuticals Price / Book for the quarter ending March 03, 2018 was 5.16 a 23.02% increase of 1.19 year over year
  • Rigel Pharmaceuticals Enterprise Value for the quarter ending March 03, 2018 was $406m a 41.78% increase of 169m year over year
View Chart On Koyfin

Quarterly RIGL EV / EBITDA (ltm) Data

11/20140.12
11/20140.05
11/20140.02
11/20140.05
10/20140.03
10/20140.05
10/20140.10
10/20140.16
10/20140.25
10/20140.18

Annual RIGL EV / EBITDA (ltm) Data

20140.12
20140.05
20140.02
20140.05
20140.03
20140.05
20140.10
20140.16
20140.25
20140.18